LOGIN  |  REGISTER
Chimerix
C4 Therapeutics

Quest Diagnostics Names Murali Balakumar Senior Vice President and Chief Information and Digital Officer

May 06, 2024 | Last Trade: US$161.59 0.08 0.05

SECAUCUS, N.J., May 6, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, announced today that Murali Balakumar, a veteran information technology healthcare business leader, has been named Senior Vice President and Chief Information and Digital Officer (CIDO).

Murali Balakumar, Senior Vice President and Chief Information and Digital Officer

Mr. Balakumar, based at the company's headquarters in Secaucus, N.J., is responsible for leading information technology, data informatics and digital solutions for Quest Diagnostics.

"Murali is a digital transformation leader with 25 years of experience designing and implementing technology strategy in the healthcare, financial services and transportation industries," said Mr. Davis. "He brings deep expertise in leading high-performance global teams and steering the design and delivery of large-scale, complex technology solutions. I'm pleased to welcome Murali to the Quest team."

Prior to joining Quest, Murali was Chief Information Officer at Oak Street Health, which was acquired by CVS Health in 2023. Prior to Oak Street, Murali was Chief Information Officer for Card Services at Fiserv and has also held IT leadership roles at JPMorgan Chase Bank and General Electric.

Mr. Balakumar earned a bachelor's degree in engineering from the Indian Institute of Technology in Chennai, India; a master's in engineering from the University of Texas; and an MBA from the University of Chicago.

About Quest Diagnostics

Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of deidentified clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 50,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. www.QuestDiagnostics.com.

Chimerix

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Compass Therapeutics

Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB